Skip to Content

'
Wei Hu, M.D., Ph.D

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Wei Hu, M.D., Ph.D. has been with M.D. Anderson since 1994. She is currently an Associate Professor in the Department of Gynecologic Oncology at MDACC. Dr.Hu received her Medical degree in 1986 and gained her Ph.D. in 1993 at the Tongii Medical University, Huazhong University of Science and Technology. She received her Postdoctoral training during the period of 1994-1997 at the University of Texas M.D. Anderson Cancer Center in the Department Gynecologic Oncology and Cellular Oncology.

 Dr. Hu’s main research interests have focused on the areas of targeting epigenetic abnormalities and tumor environment in VEGF-resistant ovarian cancer, and RNA interference based-treatment. Dr. Hu is the principal and co-investigator for several translational and preclinical studies which have been supported by peer-reviewed resources and private industries. She has published numerous peer-reviewed and invited review articles and co-authored for several book chapters. In 2009, she began collaborating with Dr. Anil K Sood on various basic and translational projects and she has been under his direct supervision. She has several joint publications with Dr. Sood and she functions as a Co-Investigator with him on several funded projects.

Dr. Hu serves on the editorial board for several journals and has been a reviewer for journals. She is an Adjunct Faculty Member at The University of Texas Graduate School of Biomedical Sciences at Houston. She is an active member of American Association of Cancer Research, International Gynecology of Cancer Society, and American Society of Clinical Oncology. 

Education & Training

Degree-Granting Education

1993 Tongji Medical University, Wuhan, China, PHD, Gynecologic Oncology
1986 Tongji Medical University, Wuhan, China, MD, Medicine

Postgraduate Training

1/1994-12/1997 Project Investigator, The University of Texas MD Anderson Cancer Center, Houston, TX
1/1986-12/1988 Resident, Department of Gynecologic Oncology, Xehe Hospital of Tongji Medical University, Wuhan

Experience/Service

Academic Appointments

Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas, Houston, TX, 4/2006-8/2012
Assistant Professor, Department of Gynecologic Medical Oncology, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, 3/2004-4/2006
Instructor, Department of Gynecologic Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, 2/2003-2/2004

Administrative Appointments/Responsibilities

Member, RNA interferecne and NC-coding Center, Houston, 6/2010-present

Other Appointments/Responsibilities

Adjunct Faculty Member, The University of Texas Graduate School of Biomedical Sciences, Houston, 2007-present

Institutional Committee Activities

Member, Complementary/ Integrative Medicine Education Resources (CIMER), 1/2003-present
Department representative, Research Sub Committee, 1/2002-2006

Honors and Awards

2010 Gynecologic Cancer Foundation Research Award, Gynecologic Cancer Foundation
2005 Institutional Reseach Award, University of Texas M.D. Anderson Cancer Center
2001 Institutional Reseach Award, University of Texas M.D. Anderson Cancer Center
2001 Pardee Foundation Research Award, Pardee Foundation
2000 The Young Investigator Award, Ovarian Cancer Research Fund

Selected Publications

Peer-Reviewed Original Research Articles

1. Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK. Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. Clin Cancer Res. e-Pub 4/2014. PMID: 24634380.
2. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK. Cross-talk between EphA2 and BRaf/CRaf Is a Key Determinant of Response to Dasatinib. Clin Cancer Res 20(7):1846-55, 4/2014. e-Pub 1/2014. PMCID: PMC3975695.
3. Tucker SL, Gharpure KM, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. MOLECULAR BIOMARKERS OF RESIDUAL DISEASE AFTER SURGICAL DEBULKING OF HIGH-GRADE SEROUS OVARIAN CANCER. Clin Cancer Res. e-Pub 4/2014. PMID: 24756370.
4. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 Pathway Alterations in Ovarian Cancer. Cancer Res. e-Pub 4/2014. PMID: 24743243.
5. Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK. Targeting Src and Tubulin in Mucinous Ovarian Carcinoma. Clin Cancer Res. e-Pub 11/2013. PMID: 24100628.
6. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs 31(5):1192-200, 10/2013. e-Pub 8/2013. PMCID: PMC3809091.
7. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK. Role of Focal Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer. J Natl Cancer Inst 105(19):1485-95, 10/2013. e-Pub 9/2013. PMCID: PMC3787907.
8. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol 128(3):506-11, 3/2013. e-Pub 11/2012. PMCID: PMC3645276.
9. Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 127(3):538-43, 12/2012. e-Pub 8/2012. PMCID: PMC3568489.
10. Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 127(1):70-4, 10/2012. e-Pub 6/2012. PMID: 22710075.
11. Lee SJ, Ghosh SC, Han HD, Stone RL, Bottsford-Miller J, Shen de Y, Auzenne EJ, Lopez-Araujo A, Lu C, Nishimura M, Pecot CV, Zand B, Thanapprapasr D, Jennings NB, Kang Y, Huang J, Hu W, Klostergaard J, Sood AK. Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma. Clin Cancer Res 18(15):4114-21, 8/2012. e-Pub 6/2012. PMID: 22693353.
12. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366(7):610-8, 2/16/2012. PMCID: PMC3296780.
13. Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des 18(19):2713-9, 2012. PMID: 22390757.
14. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 71(18):6030-9, 9/15/2011. e-Pub 7/27/2011. PMCID: PMC3174342.
15. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117(8):1661-9, 4/2011. e-Pub 11/2010. PMCID: PMC3062960.
16. Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK, Levenson V. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol 120(1):113-20, 1/2011. e-Pub 11/2010. PMCID: PMC3004216.
17. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18(2):185-97, 8/2010. PMCID: PMC2923653.
18. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 120(5):1515-23, 5/2010. e-Pub 4/12/2010. PMCID: PMC2860925.
19. Zheng H, Hu W*, Deavers MT, Shen DY, Fu S, Li YF, Kavanagh JJ. Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. Am J Obstet Gynecol 201(4):367.e1-6 Corresponding author, 10/2009. e-Pub 7/2009. PMID: 19608149.
20. Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol 200(2):177.e1-9, 2/2009. e-Pub 12/25/2008. PMID: 19110234.
21. Jaishuen A, Jimenez C, Sirisabya N, Li Y, Zheng H, Hu W, Urbauer DL, Kavanagh JJ. Poor survival outcome with moderate and severe hypercalcemia in gynecologic malignancy patients. Int J Gynecol Cancer 19(2):178-85, 2/2009. PMID: 19395991.
22. Zheng H, Hu W, Yu D, Shen DY, Fu S, Kavanagh JJ, Wei IC, Yang DJ. Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest. Pharm Res 25(10):2272-82, 10/2008. e-Pub 5/2008. PMID: 18509599.
23. Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 17(4):739-63, Jul-Aug, 7/2007. e-Pub 2/16/2007. PMID: 17309673.
24. Melichar B, Patenia R, Gallardo S, Melicharova K, Hu W, Freedman RS. Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecol Oncol 104(3):707-13, 3/2007. PMID: 17166566.
25. Li YF, Hu W, Fu S, Li JD, Liu JH, Kavanagh JJ. Aromatase Inhibitor in Ovarian Cancer: Is There A Role? International Journal of Gynecologic Cancer 17:1-15, 2007, 2007.
26. Li YF, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ. Pegylated Liposomal Doxorubicin Treatment in Recurrent Gynecologic Cancer Patients with Renal Dysfunction. Gynecol Oncol 106(2):375-380, 2007. e-Pub 5/18/2007. PMID: 17512575.
27. Fu S, Kavanagh JJ, Hu W, Bast RC, Jr. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer 16(5):1717-32, 9/2006. PMID: 17009963.
28. Fu S, Hu W, Kavanagh JJ, Bast RC, Jr. Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets 10(1):77-85, 2/2006. PMID: 16441230.
29. Hu W, Kavanagh JJ, Deaver M, Johnston DA, Freedman RS, Verschraegen CF, Sen S. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res 15(1):49-57, 2005. PMID: 15839305.
30. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 11(1):113-22, 2005. PMID: 15671535.
31. Melichar B, Konopleva M, Hu W, Melicharova K, Andreeff M, Freedman RS. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol Oncol 93(1):149-54, 4/2004. PMID: 15047229.
32. Verschraegen CF, Kudelka AP, Hu W, Vincent M, Kavanagh JJ, Loyer E, Bastien L, Duggal A, De Jager R. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemother Pharmacol 53(1):1-7, 2004. PMID: 14586557.
33. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4(12):721-9, 12/2003. PMID: 14662428.
34. Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol 129(10):549-55, 10/2003. PMID: 14513369.
35. Hu W, Wu W, Verschraegen CF, Chen L, Mao L, Yeung SC, Kudelka AP, Freedman RS, Kavanagh JJ. Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics 3(10):1904-11, 10/2003. PMID: 14625852.
36. Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Volker P, Kavanagh J, Steger M, Schulz KD, Emons G. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol 90(3):552-9, 9/2003. PMID: 13678723.
37. Melichar B, Hu W, Patenia R, Melicharova K, Gallardo ST, Freedman R. rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. J Transl Med 1(1):5, 9/2003. PMID: 14572312.
38. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC, Jr, Kudelka AP, Kavanagh JJ, Giovanella BC. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res 9(2):845-52, 2/2003. PMID: 12576458.
39. Yin TJ, Gu MJ, Zhou YK, Zheng W, Hu W, Lu YP. Determination of progesterone receptor by chemiluminescent enzyme immunoassay. Journal of Huazhong University of Science and Technology 23(1):60-61, 2003.
40. Wu W, Hu W, Kavanagh JJ. Proteomics in cancer research. Int J Gynecol Cancer 12(5):409-23, 9/2002. PMID: 12366655.
41. Hu W, Verschraegen CF, Wu WG, Nash M, Freedman RS, Kudelka A, Kavanagh JJ. Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines. Int J Gynecol Cancer 12(2):202-7, 3/2002. PMID: 11975681.
42. Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis 19(4):319-26, 2002. PMID: 12090472.
43. Hu, W*, Wu WG, Sai-Ching Jim Yeung, Kavanagh JJ, Freedman RS, Verschraegen CF. Increased Expression Of HSP 70 In Ovarian Cancer and Mesothelioma Cells following Treatment with Manumycin, a Farnesyl Transferase Inhibitor. Anticancer Res 22:665-672, 2002.
44. Verschraegen CF, Kavanagh JJ, Loyer E, Bodurka-Bevers D, Kudelka AP, Hu W, Vincent M, Nelson T, Levenback C. Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer 92(9):2327-33, 11/2001. PMID: 11745287.
45. Hu W, Wu W, Nash MA, Freedman RS, Kavanagh JJ, Verschraegen CF. Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines. Anticancer Res 20(2A):729-33, 3/2000. PMID: 10810347.
46. Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP, Verschraegen CF. Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metastasis 18(1):83-8, 2000. PMID: 11206843.
47. Boiko IV, Mitchell MF, Hu W, Pandey DK, Mathevet P, Malpica A, Hittelman WN. Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial. Clin Cancer Res 4(6):1383-91, 6/1998. PMID: 9626454.
48. Boiko IV, Mitchell MF, Pandey DK, White RA, Hu W, Malpica A, Nishioka K, Boone CW, Atkinson EN, Hittelman WN. DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 6(10):849-55, 10/1997. PMID: 9332769.
49. Hu W, Mitchell MF, Boiko IV, Linares A, Kim HG, Malpica A, Tortolero-Luna G, Hittelman WN. Progressive dysregulation of proliferation during cervical carcinogenesis as measured by MPM-2 antibody staining. Cancer Epidemiol Biomarkers Prev 6(9):711-8, 9/1997. PMID: 9298579.

Invited Articles

1. Saad AF, Hu W, Sood AK. Microenvironment and Pathogenesis of Epithelial Ovarian Cancer. Horm Cancer 1(6):277-90, 12/2010. PMCID: PMC3199131.
2. Tao X, HS Chon, Fu SQ, Kavanagh JJ, and Hu W. Update on Aurora kinase inhibitors in Gynecologic malignancies. Recent Pat Anticancer Drug Discov 3(3):162-77, 11/2008. PMID: 18991785.
3. Tao X, Hu W, Kavanagh JJ. Chemotherapy for recurrent and metastatic cervical cancer. Journal of Gynecology Oncology 116(3 Suppl 2):s67-71, 9/2008.
4. Hong Z, Kavanagh JJ, Hu W, Bast R, Fu SQ.. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 17(2):325-38, Mar-Apr, 2007. PMID: 17362310.
5. Chon HS, Hu W*, Kavanagh JJ. Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets 6(4):333-63, 6/2006. PMID: 16848724 * Corresponding author.
6. Fu SQ, Hu W, Kavanagh JJ, Bast R. Clinical Application of Oxaliplatin in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer 16:1717-1732, 2006, 2006.
7. Li YF, Hu W, Fu SQ, Kavanagh JJ. Proteomics in Gynecologic Malignancies: Advances to Date. American Journal of Cancer 5(5):299-317, 2006, 2006.
8. Fu SQ, Hu W, Kavanagh JJ, Bast R. Targeting aurora kinases in ovarian cancer. Expert Opin Ther 10(1), 2006, 2006.
9. Hu W, Wu W, Kobayashi R, Kavanagh JJ. Proteomics in cancer screening and management in gynecologic cancer. Curr Oncol Rep 6(6):456-62, 11/2004. PMID: 15485615.
10. See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 13(6):701-34, 11/2003. PMID: 14675307.

Abstracts

1. Edna M. Mora, Chad V. Pecot, Lingegowda S. Mangala, Hee Dong Han, Pablo Vivas-Mejias, Bokyung Sung, Masato Nishimura, Koji Matsuo, Sankar Kannan, Patrick A. Zweidler-McKay, Rene Nieves Alicea, Guillermo N. Armaiz-Peña, Mian M.K. Shahzad, Shyon Haghpeykar, Alpa M. Nick, Rebecca L. Stone, Jinsong Liu, Hu W ,Bharat B. Aggarwal, Gabriel López Berestein, David Jackson, Anil K. Sood. Erythropoietin Met a New Receptor. AACR, 2010.
2. Fu S, Li Y, Shen DY, Hong Z, Bast RC, Kavanagh J, Sood AK, and Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of Histone 3. Amer Assoc Ca Res, 2009.
3. Hong Z, Hu W, Deavers M, Shen DY, Li YF, Kavanagh JJ. Frequent expression of Aurora kinase A , but not aurora kinase B in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Cancer. IGCS 2008 Proceedings. International Journal of Gynecological Cancer 18(6), 11/2008, 11/2008.
4. Bast RC, Iyer R, Hu W, Kavanagh JJ, Coleman R, Levenback C, Sood A, Wolf J, Gershenson DM, Markman M, Fu S. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer. ASCO Proceedings. Journal of Clinical Oncology, 2008, 2008.
5. Kavanagh JJ, Hu W, Fu SQ, Deavers M, Moore C, Coleman RL, Levenback CF, Shen DY, Zheng H, Li YF, Mueller P, Gershenson DM. Anti-tumor Activity of Letrozole in Patients with Recurrent Advanced Low Malignant Potential or Low Grade Serous Ovarian Tumors. Journal of Clinical Oncology. Journal of Clinical Oncology 18 S(5582), 2007, 2007.
6. Zheng H, Hu W, Deavers M, Shen De-yu, Fu SQ, Li YF, Kavanagh JJ. Cyclin G Expression in Low Grade Ovarian Tumors and Recurrent Ovarian Cance. Clinical Cancer Research, 2007, 2007.
7. Fu S, Kavanagh JJ, Hu W, Li YF, Moore C, Bast R, Perry G, Wolf J, Coleman R, Gershenson DM. A Phase I Study of a Hypomethylating Agent Azacitidine in Combination with Carboplatin in Patients with Platinum Resistant Epithelial Ovarian Cancer. Seattle Ovarian Cancer Meeting, 2006, 2006.
8. Fu S, Kavanagh JJ, Perry G, Hu W, Moore C, Wolf J, Coleman RL, Gershenson DM, Yu YH, Bast R. A phase I study of a hypomethylating agent azacitine in combination with carboplatin in patients with platinum resistant epithelial ovarian cance. ASCO, 2006, 2006.
9. Hu, W, Chen L, Wu WG, Bolanos-Clark M, Verschraegen CF, Yeung SJ, Kudelka AP, Freedman RS, Kavanagh JJ. Enhancing Tumor Killing With the Combined Treatment of Manumycin and Paclitaxel in Paclitaxel- Resistant Ovarian Cancer Cells. American Association of Cancer Research, 2004.
10. Hu W, Kavanagh JJ, Deavers M, Fu SQ, Johnston DA, Freedman RS, Verschraegen CF Sen S. Frequent over-expression of STK15/AURORA-A/BTAK and Chromosomal Instability in Tumorigenic Cell Cultures Derived from Human Ovarian Cancer. American Association of Cancer Research, 2004, 2004.
11. Wang, E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM. Peritoneal and sub-peritoneal stroma may facilitate regional spread of ovarian cancer. American Association of Cancer Research, 2004.
12. Hu, W , Wu WG , Verschraegen CF, Chen L, Mao L, Yeung SJ, Kudelka AP, Freedman RS, Kavanagh JJ. Proteomic identification of Heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. American Association of Cancer Research, 2003.
13. Hu, W, Wu W, Verschraegen CF, Lu K, Liu J, Yung MS, Vincent M, Kudelka AP, Freedman RS, Kavanagh JJ. Differential Protein Profile Analysis of Sera from Normal Donors and Ovarian Cancer Patients by Proteomics. American Association of Cancer Research, 2002.
14. Hu, W, Verschraegen CF, Wu WG, Freedman RS, Kudelka AP, Kavanagh JJ, Yeung SCJ. Enhanced Apoptotic Effect of Heat Shock Protein Inhibitor in Combination with Farnesyl Transferase Inhibitors (FTI) on Ovarian and Mesothelioma Cancer Cells. American Association of Cancer Research, 2002.
15. Wu, W, Hu W, Hong WK, Mao L. Rapid Screening and Identification of Serum Markers In Patients With Resectable Non-Small Cell Lung Cancer. American Association of Cancer Research, 2002.
16. Hu, W, Wu W, Rui A, Yeung S, Smith JA, Kavanagh JJ, Verschraegen CF. Dynamic changes in the protein profile of ovarian cancer cell line 2774 after treatment with a farnesyl transferase inhibitor (FTI). Clinical Cancer Research 7((11)):201 Suppl, 2001.
17. Hu, W, Wu WG, Aoki Rui, Sai-Ching Yeung J, Smith J, Kavanagh JJ, Verschraegen CF. Dynamic Changes In The Protein Profile Of Ovarian Cancer Cell Line 2774 After Treatment With A Farnesyl Transferase Inhibitor (FTI). Molecular target and Cancer. Therapeutics meeting, 2001.
18. Verschraegen, CF, Hu W, Freedman RS, Kudelka A, Kavanagh JJ, Sai-Ching Jim Yeung. Growth Inhibitory Effect of FTI Alone and in Combination with Quercetin on Ovarian Cancer Cell Lines. American Association of Cancer Research, 2001.
19. Hu, W, Wu WG, Sai-Ching Jim Yeung, Kavanagh JJ, Freedman RS, Mao L, Verschraegen CF. Increased Expression of HSP 70 In Ovarian Cancer Cell Line Following Treatment With FTI. American Association of Cancer Research, 2001.
20. Verschraegen, CF, Hu W, Devers M, Mendoza J, Kudelka AP, Freedman RS, Kavanagh JJ, McCrea PD. Expression of Fascin in the Cell Lines Derived from Ovarian Cancer. Proceeding of Beatson International Cancer Conference(A128), 2000.
21. Hu, W, Kavanagh JJ, Deavers M, Johnston DA, Freedman RS, Verschraegen CF Sen S. Frequent over-expression of STK15/AURORA-A/BTAK and Chromosomal Instability in Tumorigenic Cell Cultures Derived from Human Ovarian Cancer. American Association of Cancer Research, 2000.
22. Verschraegen, CF, Hu W, Nash MA, Freedman RS, Kudelka AP, Kavanagh JJ. Growth Inhibitory Effect of SB-75, a LHRH Antagonist, on Ovarian Cancer Cell Cultures. Proceeding of International Gynecologic Cancer Socienty, 2000.
23. Hu, W, Verschraegen CF, Deavers M, Kudelka AP, Kavanagh JJ, McCrea PD. Increased Expression of Fascin, a Motility Associated Protein, in Cell Cultures Derived from Ovarian Cancer and in Borderline and Carcinomatous Ovarian Tumors. Proceeding of International Gynecologic Cancer Socienty, 2000.
24. Hu, W, Wu W, Kuang J, Mendoza J, Kudelka AP, Freedman RS, Kavanagh JJ, Sen S, Zhou HY, Verschraegen C. Overexpression of STK15/BTAK Correlates with Increased Malignancy of Ovarian Cancer Cell Lines. American Academy of Cancer Research(A2458):371, 2000.
25. Verschraegen, CF, Hu W, Wu WG, Mendoza J, Freedman RS, Kudelka A, Kavanagh JJ. The Effect of Growth Inhibition by ALRT1550 on ovarian cancer cells. American Association of Cancer Research:A1746, 2000.
26. Hu, W, Verschraegen C, Wu WG, Mendoza J, Freedman RS, Kudelka A, Kavanagh JJ. The Effect of Growth Inhibition By ALRT1550 on Retinoid–Resistant Ovarian Cancer Cell Lines. J Immnunotherapy 22((5)):460(A), 2000.
27. Verschraegen, C, Hu W, Mendoza J, Du Y, Kudelka AP, Freedman RS, Kavanagh JJ, Giovanella B. Characterization of Twenty-Three Mullerian Cell Lines Derived from Primary Ovarian Cancers. American Academy of Cancer Research A3291:499, 1999.
28. Kavanagh, JJ, Winn R, Steger M, Nelson-taylor T, Edwards K, Rodgers R , Borst J, Kudelka AP, Hu W, Verschraegen CF. Docetaxel For Patients with Ovarian Cancer Refractory to Paclitaxel, An Update. Proceeding of American Society of Clinical Oncology 18(A1423), 1999.
29. Verschraegen, CF, Mansfield BW, Steger M, Wu QP, Maclean D, Siddik Z, Perez-Soler R, Hu W, Kudelka AP, Kavanagh JJ, Khokhar AR. Phase I study of Intraperitoneal Liposomal Cisplatin Analog L-NDDP For Treatment Of Peritoneal Carcinomatosis. Proceeding of American Society of Clinical Oncology 18(A1405,), 1999.
30. Stegger, M, Kudelka AP, Freedman RS, Verschraegen CF, Hu W, Du Y, Kavanagh JJ. Phase II of SB-75 A LHRH Antagonist in Patients with Ovarian Cancer. Proceeding of American Society of Clinical Oncology 18(A1398), 1999.

Book Chapters

1. Aiping Chen, M.D., Zhaoxia Ding, Anil K Sood, Wei Hu*. Hormonal therapy in ovarian cancer, in Encyclopedia of Cancer. In: Hormonal Therapy of Ovarian Cancer. Second edition, e-Book 2011.
2. Hu, W, Kavanagh JJ. Apoptosis –Inducing Anticancer Drugs in Clinical Trials. In: Application of apoptosis to Cancer Treatement. Chapter 15. Kluwer Academic Publisher, 2005.
3. Hu, W, Kavanagh JJ. Hormones and Epithelial Ovarian Cancer. In: Ovarian Malignancy. ISIS Medica, 2000.

Last updated: 5/7/2014